Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years

Phase 4 Completed 108 enrolled Assistance Publique - Hôpitaux de Paris

RandomizedParallel-groupOpen-labelTreatment

Summary

The aim of this trial is to lower the morbidity rate in elderly patients affected with systemic necrotizing vasculitides, by reducing mortality and improving global outcome.

Timeline

Start: 2005-07
Primary completion: 2011-07
Completion: 2011-07

Publications

Pagnoux C, Quemeneur T, Ninet J, Diot E, Kyndt X, de Wazieres B, Reny JL, Puechal X, le Berruyer PY, Lidove O, Vanhille P, Godmer P, Fain O, Blockmans D, Bienvenu B, Rollot F, Ait el Ghaz-Poignant S, Mahr A, Cohen P, Mouthon L, Perrodeau E, Ravaud P, Guillevin L; French Vasculitis Study Group. Treatment of systemic necrotizing vasculitides in patients aged sixty-five years or older: results of a multicenter, open-label, randomized controlled trial of corticosteroid and cyclophosphamide-based induction therapy. Arthritis Rheumatol. 2015 Apr;67(4):1117-27. doi: 10.1002/art.39011.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Azathioprine	Small molecule	—	—
Subject	Cyclophosphamide	Other / unclassified	500 mg	Intravenous
Subject	Cyclophosphamide	Other / unclassified	500 mg/m2	Intravenous
Subject	Methylprednisolone	Other / unclassified	—	—
Subject	Prednisone	Other / unclassified	—	—
Background	Methotrexate	Small molecule	—	—
Background	Mycophenolate Mofetil	Small molecule	—	—

Treatment of Necrotizing Vasculitides for Patients Older Than 65 Years

Summary

Timeline

Publications

Drugs

Indications